de Lemos, James A.
Navar, Ann Marie
Article History
First Online: 9 June 2022
Competing interests
: J.A.d.L. has received personal fees for participating in steering or data safety monitoring committees from Amgen, Regeneron, Verve Therapeutics, Novo Nordisc, Eli Lilly and Astra Zeneca. A.M.N. has received funding for research to her institution from BMS, Esperion, Amgen, and Janssen, and personal fees from Amarin, Amgen, Astra Zeneca, BI, Bayer, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, New Amsterdam, and Pfizer.